DW

David M. Weiner

AP Acadia Pharmaceuticals: 19 patents #3 of 83Top 4%
Overall (All Time): #236,990 of 4,157,543Top 6%
19
Patents All Time

Issued Patents All Time

Showing 1–19 of 19 patents

Patent #TitleCo-InventorsDate
10525046 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2020-01-07
10028944 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2018-07-24
9566271 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2017-02-14
9211289 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2015-12-15
8921393 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2014-12-30
8618130 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldan 2013-12-31
8377959 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2013-02-19
8227487 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2012-07-24
8008323 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2011-08-30
7994193 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2011-08-09
7875632 Selective serotonin receptor inverse agonists as therapeutics for disease Robert E. Davis, Mark R. Brann 2011-01-25
7863296 Selective serotonin receptor inverse agonists as therapeutics for disease Robert E. Davis, Mark R. Brann, Norman Nash 2011-01-04
7820695 Selective serotonin receptor inverse agonists as therapeutics for disease Robert E. Davis, Mark R. Brann 2010-10-26
7732462 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2010-06-08
7713995 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Norman Nash, Carl-Magnus A. Andersson, Allan K. Uldam 2010-05-11
7659285 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2010-02-09
7601740 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam 2009-10-13
7348140 Clinical indications for genotyping polymorphic variants of G-protein coupled receptors Mark R. Brann, Ethan S. Burstein, Jakob L. Hansen, Fabrice Piu, Andria Lee 2008-03-25
6358698 Methods of identifying inverse agonists of the serotonin 2A receptor Mark R. Brann 2002-03-19